Eribulin approved for metastatic breast cancer

Approved in 2010 by US FDA and late 2015 by IRN FDO , the drug now opens a new chapter for patients with metastatic breast cancer who previously have tried 2 drugs and failed .

the dramatic and promising results prompted FDA to take an extraordinary measure and approve it immediately . FDO approved the drug later in 2015 after more extensive research .

Eribulin which is the generic name for the drug "Halaven" .

most common adverse effects are : 1-neutropenia : that is the lowered count in white blood cells 2- lowered RBC count 3- alopecia : the falling of hair 4-neuropathy : some problems with nerves in extremities and other places which causes tingling , ....

5-long Q-T syndrome : heartbeat changes which can be fatal in very extreme forms 6- constipation

these are the most common adverse effects . as you might know these drugs work by lowering the turnover (the reproduction) in all body cells esp. cancer cells . why ? because cancer cells reproduce more .

www.ncbi.nlm.nih.gov...

in my own experience this drug had acceptable efficacy and lower adverse effects compared to other drugs available on the market which makes it a viable option .

a reply to: haman10
you also want to take Iodine and stop using deodorant with parabens in. here is a study on using Artemesinin ( a chinese herb)which in one study killed 96% of breast cancer cells in something like 16 hours
www.news-medical.net...
www.ncbi.nlm.nih.gov...